Étiquette : neurophysiologie

Bibliographie Cannabis et Cannabinoïdes en Neurologie, Docteur Christian SUEUR, GRECC, mars 2020

Bibliographie Cannabis et Cannabinoïdes en Neurologie   Docteur Christian SUEUR, GRECC, mars 2020.     Cannabinoïdes et Sclérose en Plaque, p 2. Cannabinoïdes et Migraines, p 4. Cannabinoïdes et maladies neurodégénératives, p 4. Cannabinoïdes et Maladie de Parkinson, p 6. Cannabinoïdes et Maladie de Huntington, p 7. Cannabinoïdes et Maladie d’Alzheimer, p 8.  

Lire la suite

Neuroprotective Effect of Cannabidiol Against Hydrogen Peroxide in Hippocampal Neuron Culture, Jungnam Kim et al. 2020

Neuroprotective Effect of Cannabidiol Against Hydrogen Peroxide in Hippocampal Neuron Culture Jungnam Kim, Ji Yu Choi, Jeongyeon Seo, and Insung S. Choi Cannabis and Cannabinoid Research, 2020,Volume X, Number X, Doi : 10.1089/can.2019.0102   Abstract Introduction: Reports on the neurotoxic and neuroprotective effects of cannabidiol (CBD) have not been in complete accord, showing different and somewhat contradictory results depending upon the brain cell types and experimental conditions employed. This work systematically examines the neuroprotective capability of CBD against oxidative stress (i.e., hydrogen peroxide [H2O2]) as well as its toxicity profile in the in vitro culture platform of primary hippocampal neurons. Materials and Methods: The low cell-density (100 neurons [...]

Lire la suite

Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats, Ewa Kozela et al., 2019

Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats Ewa Kozela & Martyna Krawczyk & Tomasz Kos & Ana Juknat & Zvi Vogel & Piotr Popik Molecular Neurobiology, 2019, Doi : 10.1007/s12035-019-01831-2   Abstract Cannabidiol (CBD), a non-psychotropic cannabinoid, demonstrates antipsychotic-like and procognitive activities in humans and in animal models of schizophrenia. The mechanisms of these beneficial effects of CBD are unknown. Here, we examined behavioral effects of CBD in a pharmacological model of schizophrenia-like cognitive deficits induced by repeated ketamine (KET) administration. In parallel, we assessed transcriptional changes behind CBD activities in the prefrontal cortex (PFC), the [...]

Lire la suite

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats, Karina Genaro et al., 2017

Cannabidiol Is a Potential Therapeutic for the Affective-Motivational Dimension of Incision Pain in Rats Karina Genaro, Débora Fabris, Ana L. F. Arantes, Antônio W. Zuardi, José A. S. Crippa and Wiliam A. Prado Frontiers in Pharmacology, June 2017 | Volume 8 | Article 391 doi : 10.3389/fphar.2017.00391   Background : Pain involves different brain regions and is critically determined by emotional processing. Among other areas, the rostral anterior cingulate cortex (rACC) is implicated in the processing of affective pain. Drugs that interfere with the endocannabinoid system are alternatives for the management of clinical pain. Cannabidiol (CBD), a phytocannabinoid found in Cannabis sativa, has been utilized [...]

Lire la suite

Neurocognitive Consequences of Chronic CannabisUse : A Systematic Review and Meta-Analysis, Pedro Rafael Figueiredo et al., 2019

Neurocognitive Consequences of Chronic CannabisUse : A Systematic Review and Meta-Analysis Pedro Rafael Figueiredo, Serenella Tolomeo, J. Douglas Steele, Alexander Baldacchino Neuroscience and Biobehavioral Reviews, 2019 Doi : 10.1016/j.neubiorev.2019.10.014   "Une méta-analyse échoue à mettre en évidence une "toxicité" de l'usage du cannabis à long terme, sur les fonctions neuropsychologiques cognitives"   Highlights  A meta-analysis was conducted to assess the neuropsychological impact of cannabis.  A limited association was found between chronic cannabis use and neurocognitive deficits.  Memory and chronic cannabis smoking were linked. ABSTRACT Cannabis is currently the most used illicit substance in the world with a global widespread distribution. Although its acute neurocognitive effects on human behaviour have [...]

Lire la suite

Classic Hallucinogens and Mystical Experiences : Phenomenology and Neural Correlates, Frederick S. Barrett & Roland R. Griffiths, 2018

Classic Hallucinogens and Mystical Experiences : Phenomenology and Neural Correlates Frederick S. Barrett, Roland R. Griffiths Current Topics in Behavioral Neurosciences, 2018, 36, 393–430. doi : 10.1007/7854_2017_474   Abstract This chapter begins with a brief review of descriptions and definitions of mystical-type experiences and the historical connection between classic hallucinogens and mystical experiences. The chapter then explores the empirical literature on experiences with classic hallucinogens in which claims about mystical or religious experiences have been made. A psychometrically validated questionnaire is described for the reliable measurement of mystical-type experiences occasioned by classic hallucinogens. Controlled laboratory studies show that under double-blind conditions that provide significant controls for [...]

Lire la suite

Modern Clinical Research on LSD, Matthias E Liechti, 2017

Modern Clinical Research on LSD Matthias E Liechti Neuropsychopharmacology, 2017, 42, 2114–2127. doi : 10.1038/npp.2017.86   All modern clinical studies using the classic hallucinogen lysergic acid diethylamide (LSD) in healthy subjects or patients in the last 25 years are reviewed herein. There were five recent studies in healthy participants and one in patients. In a controlled setting, LSD acutely induced bliss, audiovisual synesthesia, altered meaning of perceptions, derealization, depersonalization, and mystical experiences. These subjective effects of LSD were mediated by the 5-HT2A receptor. LSD increased feelings of closeness to others, openness, trust, and suggestibility. LSD impaired the recognition of sad and fearful faces, reduced left [...]

Lire la suite

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression, Paulo R. Shiroma et al., 2014

Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression Paulo R. Shiroma, C. Sophia Albott, Brian Johns, Paul Thuras, Joseph Wels and Kelvin O. Lim The International Journal of Neuropsychopharmacology, 2014, Volume 17, Issue 11, 1805–1813, Doi : 10.1017/S1461145714001011   Abstract The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid anti-depressant effects in treatment-resistant depression (TRD). However, evaluation of ketamine's neurocognitive aspects in TRD has started to be explored. This study aims to (1) examine baseline neurocognitive performance and change in severity of depressive symptoms through six ketamine infusions, (2) examine the neurocognitive effects after completion of serial infusions and whether changes were associated to [...]

Lire la suite